Carlyle Builds Diverse Generic Platform With India’s Viyash Life Sciences
Global Private Equity Fund First Invested In Firm In June 2021
Viyash Life Sciences said it intended to seek further investment opportunities to build scale after establishing an integrated generic pharmaceutical platform in India in partnership with the private equity giant Carlyle.
You may also be interested in...
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.